Literature DB >> 20535997

[Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice].

E A Kozina, V G Khaindrava, V S Kudrin, V G Kucherianu, P D Klodt, E V Bocharov, K S Raevskiĭ, G N Kryzhanovskiĭ, M V Ugriumov.   

Abstract

The dopaminergic nigrostriatal system is a key component of regulation of the motor behaviour. Cell bodies of dopaminergic DA-ergic neurons are located in the compact zone of the substantia nigra, and their axons are projected along the nigrostriatal tract to the striatum. This study was aimed to develop an experimental model of the functional insufficiency of the DA-ergic neurons of the nigrostriatal system without any manifestation of movement disorders, i.e., a model of presymptomatic stage of parkinsonism. This model has been developed with a single subcutaneous injection of a low dose of MPTP (12 mg/kg) which is converted in the brain into the MPP+, a neurotoxin of DA-ergic neurons. It has been shown that the MPTP injection on the 14th day is followed by: (a) absence of any sign of movement disorders; (b) no change in the DA content and the number of DA-ergic neurons in the substantia nigra; (c) substantial loss of DA in the striatum as a result of the degeneration of about 50% of DA-ergic axons. The absence of movement disorders under the substantial DA depletion and degradation of DA-ergic axons in the striatum is supposed to be a consequence of the turning on of the compensatory processes in the brain. Thus, we have developed the experimental model of presymptomatic stage of parkinsonism which is characterized by the degeneration of DA-ergic axons in the striatum without degradation of the neuron cell bodes in the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535997

Source DB:  PubMed          Journal:  Ross Fiziol Zh Im I M Sechenova        ISSN: 0869-8139


  4 in total

1.  Dopamine synthesis in the nigrostriatal system at the presymptomatic and early symptomatic stages in parkinsonian mice.

Authors:  G R Khakimova; E A Kozina; A Ya Sapronova; M V Ugrumov
Journal:  Dokl Biol Sci       Date:  2011-12-02

2.  Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson's disease.

Authors:  Fatma Y Meligy; Dalia A Elgamal; Eman S H Abd Allah; Naglaa K Idriss; Nagwa M Ghandour; Ehab M R Bayoumy; Azza Sayed Abdelrehim Khalil; Mohamed M El Fiky; Mostafa Elkhashab
Journal:  Mol Biol Rep       Date:  2019-08-08       Impact factor: 2.316

3.  Effects of intravenous human umbilical cord blood CD34+ stem cell therapy versus levodopa in experimentally induced Parkinsonism in mice.

Authors:  Noha Abo-Grisha; Soha Essawy; Dina M Abo-Elmatty; Zenab Abdel-Hady
Journal:  Arch Med Sci       Date:  2013-11-29       Impact factor: 3.318

4.  Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity.

Authors:  Soha S Essawy; Mona Kamal Tawfik; Horya Erfan Korayem
Journal:  Arch Med Sci       Date:  2017-04-20       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.